RELATIVITY-123 MSS CRC unlikely to reach primary endpoint and will be discontinued
Other trials evaluating fixed-dose combinations of nivolumab and leratorimab as treatments for other tumor types will continue. The phase 3 RELATIVITY-123 trial (NCT05328908) tested nivolumab (Opdivo) and relatlimab (Opdurag) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) who had disease progression after 1 to 4 days. ) is evaluating the effectiveness of combination […]
Sacral nerve stimulation market expected to reach USD 16.6 billion by 2032 | CAGR of 10.3% from 2023 to 2032
Allied Market Research has published a report titled: “Sacral nerve stimulation market By product type (devices and accessories) By application (urinary incontinence, fecal incontinence, chronic anal fissures, etc.) End users (hospitals, specialty clinics, etc.): Global opportunity analysis and industry forecasts, 2023-2032. ” According to the report, the global sacral nerve stimulation industry is estimated at […]
Global anal cancer rapid diagnostic test market is projected to reach a value of $669.25 million by 2030
In 2022, Global rapid diagnostic test for anal cancer market It is valued at $598.8 million and the market size is projected to reach $669.25 million by 2030. The market is projected to grow at a CAGR of 1.4% over the forecast period 2023-2030. The rapid diagnostic test for anal cancer market is an important […]